# Europe CRO Market

> Europe CRO Market Research Report Information By Service Type (Early Phase Development Services, Clinical, Laboratory Service, and Others), By Application (Oncology, Neurology, Cardiology, Infectious Disease, Metabolic Disorder, Renal/Nephrology, and Others), By End-user (Pharmaceutical & Biotech Companies, Medical Device Companies, Academic & Research Institutes, and Others), And By Region (Germany, France, UK, Italy, Spain, and Rest of Europe) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.0%
- **2024:** $ 23.6 Billion
- **2025:** $ 25.17 Billion
- **2035:** $ 44.81 Billion
- **Key Players:** IQVIA (GB), Covance (GB), PAREXEL International (GB), Charles River Laboratories (US), Syneos Health (US), Medpace (US), PPD (US), Clinipace (US), Wuxi AppTec (CN)

**Report ID:** MRFR/HC/11110-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/europe-cro-market-12633

---

## Market Summary

## **Europe CRO Market Overview**

As per MRFR analysis, the Europe CRO Market Size was estimated at 23.04 (USD Billion) in 2024. The Europe CRO Market Industry is expected to grow from 24.60 (USD Billion) in 2025 to 44.49 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.80% during the forecast period (2025 - 2034). Increased health concerns and challenges have led to more expensive operations, and more bariatric procedures are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **CRO Market Trends**

### **Growing demand for virtual and decentralized clinical trials is driving the market growth**

The demand for virtual and decentralized clinical trials has increased at the fastest Market CAGR. The implementation of remote monitoring and patient-centric approaches has been expedited due to the COVID-19 pandemic, resulting in a decreased necessity for in-person site visits. This phenomenon improves the efficiency of patient recruitment, retention, and data acquisition, thereby increasing the accessibility and inclusivity of clinical trials. By integrating digital technologies, telemedicine, and data analytics, CROs are fostering a clinical trial environment that is more adaptable and robust.

Furthermore, pragmatic clinical trials and real-world evidence (RWE) are gaining increasing attention. Various stakeholders, such as regulatory bodies and healthcare providers, are acknowledging the value of integrating real-world data with conventional clinical trial data. This integration aims to enhance comprehension of treatment efficacy and safety across diverse patient populations. Clinical Research Organizations (CROs) are assuming a crucial function in the development and implementation of pragmatic trials that mirror routine clinical practice. This enables CROs to offer insights that extend beyond the controlled setting of conventional trials.

Consistent with the industry's overarching transition towards research methodologies that prioritize patient outcomes and are more patient-centric, this trend impacts the strategic trajectory of CROs that operate within the European market. Thus driving the CRO market revenue.

## **CRO Market Segment Insights**

### **CRO Service Type Insights**

The Europe CRO market segmentation, based on Service Type, includes early Phase Development Services, [Clinical, Laboratory Services](../../../reports/clinical-laboratory-services-market-7145), and Others. Clinical services represent the most substantial sector within the European CRO market, primarily propelled by the escalating intricacies associated with clinical trials. Pharmaceutical and biotechnology companies are increasingly delegating clinical trial operations to CROs in order to capitalize on their specialized knowledge, expedite trial schedules, and effectively manage regulatory obligations. This demand for all-encompassing clinical services drives the expansion of this sector within the European CRO industry.

### **CRO Application Insights**

The Europe CRO market segmentation, based on Application, includes Oncology, Neurology, Cardiology, Infectious Disease, Metabolic Disorder, Renal/Nephrology, and Others. The European CRO market is witnessing the emergence of oncology as the largest segment, driven by the growing emphasis on cancer research and the elevated incidence of oncological disorders. Pharmaceutical companies utilize CROs due to the intricate nature of oncology trials, which necessitates specialized knowledge and a strong approach to patient recruitment. As a result, this sector experienced significant expansion.

### **CRO Service End-user Insights**

The Europe CRO market segmentation, based on End-users, includes Pharmaceutical and biotech Companies, Medical Device Companies, Academic and Research Institutes, and Others. Pharmaceutical and biotechnology companies constitute the largest segment of the European CRO market, which is being driven by the increasing trend of outsourcing. In order to streamline research processes, reduce expenses, and expedite drug development schedules, these organizations pursue CRO expertise. By harnessing external capabilities, they are able to outsource, which guarantees a concentration on fundamental capabilities and improves the overall efficacy of research and development undertakings.

**Figure 1: Europe CRO Market, by End User, 2022 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **CRO Regional Insights**

By region, the study provides market insights into Germany, France, the UK, Italy, Spain and the rest of Europe. Germany dominates the European market due to its strong pharmaceutical and biotechnology industries, sophisticated research infrastructure, and leadership in innovation. The United Kingdom is the most rapidly expanding region, driven by technological advancements, a supportive regulatory environment, and a dynamic life sciences ecosystem. The CRO market is expanding at a faster rate in France, the second-largest region, due to its robust pharmaceutical industry, research excellence, and rising outsourcing trends.

**Figure 2: EUROPE CRO MARKET SHARE BY REGION 2022 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **CRO Key Market Players & Competitive Insights**

Leading market players in the European CRO market engage in mergers and strategic collaborations to combat the intense competition. CROs are emphasizing broadening their service portfolios and expanding their geographic reach in response to the growing demand for specialized services and other market developments. In the swiftly evolving European CRO market, companies are striving to provide comprehensive solutions to pharmaceutical and biotechnology partners, thereby intensifying competition and cultivating a dynamic environment.

### **Key Companies in the CRO market include**

- Pharmaceutical Product Development, LLC (Thermo Fisher Scientific ) (U.S.)
- [Medpace Holdings](https://investor.medpace.com/news-releases/news-release-details/medpace-donation-matthew-25-ministries-funds-delivery-relief), Inc. (U.S.)
- Parexel International Corporation (Ireland)
- IQVIA (U.S.)
- Laboratory Corporation of America Holdings (U.S.)
- [Charles River Laboratories](https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-completes-acquisition-cro-services) (U.S.)
- PHASTAR (U.K.)
- Oy 4Pharma Ltd (Finland)
- PSI (Switzerland)
- Icon plc (Ireland)

## **CRO Market Segmentation**

### **CRO Service Type Outlook**

- Early Phase Development Services
- Clinical
- Laboratory Service
- Others

### **CRO Application Outlook**

- Oncology
- Neurology
- Cardiology
- Infectious Disease
- Metabolic Disorder
- Renal/Nephrology
- Others

### **CRO End-user Outlook**

- Pharmaceutical & Biotech Companies
- Medical Device Companies
- Academic & Research Institutes
- Others

## Market Drivers

### Expansion of Outsourcing Trends

The trend of outsourcing research and development activities is gaining momentum within the Europe [Contract Research Organization](https://www.marketresearchfuture.com/reports/contract-research-organization-market-3322) Market. Pharmaceutical and biotechnology companies are increasingly recognizing the benefits of partnering with CROs to reduce costs and enhance operational efficiency. In 2025, it is projected that over 50% of clinical trials in Europe will be outsourced to CROs, reflecting a significant shift in how companies approach research. This outsourcing trend allows firms to focus on core competencies while leveraging the expertise and resources of CROs. Additionally, the competitive landscape is evolving, with CROs offering a wider range of services, including regulatory support and data management. As companies continue to seek cost-effective solutions, the demand for CRO services is likely to grow, further solidifying their role in the European research ecosystem.

### Growing Biopharmaceutical Sector

The biopharmaceutical sector in Europe is experiencing substantial growth, which significantly impacts the Europe Contract Research Organization Market. In 2025, biopharmaceuticals accounted for over 30% of the total pharmaceutical market in Europe, reflecting a shift towards biologics and personalized medicine. This trend necessitates specialized research services, which CROs are well-positioned to provide. As biopharmaceutical companies increasingly outsource clinical trials to CROs, the demand for their services is likely to rise. Additionally, the complexity of biopharmaceutical development, including the need for advanced technologies and expertise, further underscores the importance of CROs in this sector. The collaboration between biopharmaceutical firms and CROs is expected to enhance research efficiency and accelerate the time-to-market for new therapies.

### Regulatory Support and Compliance

The Europe Contract Research Organization Market benefits from robust regulatory frameworks that facilitate clinical trials and research activities. The European Medicines Agency (EMA) provides guidelines that ensure compliance with safety and efficacy standards. This regulatory support is crucial for CROs, as it enhances their credibility and operational efficiency. In 2025, the number of clinical trials conducted in Europe reached approximately 1,200, indicating a growing reliance on CROs to navigate complex regulatory landscapes. Furthermore, the harmonization of regulations across EU member states simplifies processes for CROs, allowing them to operate more effectively across borders. This regulatory environment not only fosters innovation but also attracts global pharmaceutical companies to collaborate with European CROs, thereby driving market growth.

### Increased Focus on Patient Engagement

The Europe Contract Research Organization Market is witnessing a paradigm shift towards patient-centric approaches in clinical research. There is a growing recognition of the importance of patient engagement in the design and execution of clinical trials. In 2025, approximately 60% of CROs in Europe reported implementing strategies to enhance patient involvement, such as using digital platforms for communication and feedback. This focus on patient engagement not only improves recruitment and retention rates but also ensures that trials are more aligned with patient needs and preferences. As regulatory bodies increasingly emphasize patient-centricity, CROs that prioritize this approach are likely to enhance their reputation and attract more clients. This trend is expected to drive growth in the CRO market as companies seek to improve trial outcomes and patient satisfaction.

### Technological Advancements in Research

Technological advancements are transforming the Europe Contract Research Organization Market, enabling more efficient and effective research methodologies. The integration of artificial intelligence, machine learning, and data analytics into clinical trials is becoming increasingly prevalent. These technologies allow CROs to streamline processes, enhance data accuracy, and improve patient recruitment strategies. In 2025, it is estimated that over 40% of clinical trials in Europe utilize some form of digital technology, indicating a significant shift towards tech-driven research. This trend not only reduces costs but also shortens timelines, making CROs more attractive partners for pharmaceutical companies. As technology continues to evolve, CROs that adopt innovative solutions are likely to gain a competitive edge in the market.

## Future Outlook

The Europe Contract Research Organization Market is projected to grow at a 6.0% CAGR from 2025 to 2035, driven by increasing R&D investments and demand for outsourcing.

**New opportunities:**

- Expansion of specialized clinical trial services for rare diseases.
- Development of integrated [data management platforms](https://www.marketresearchfuture.com/reports/data-management-platform-market-4573) for real-time analytics.
- Partnerships with biotech firms for accelerated drug development processes.

By 2035, the market is expected to solidify its position as a leader in clinical research services.

## Segment Insights

### By Service Type: Clinical Trials (Largest) vs. Laboratory Services (Fastest-Growing)

In the Europe Contract Research Organization Market, the service type segment is witnessing dynamic shifts, with Clinical Trials holding the largest market share. This sector predominates due to an increase in pharmaceutical research and development activities. Meanwhile, Laboratory Services are emerging rapidly, attributed to the growing demand for advanced diagnostic testing and the need for efficient laboratory management solutions. This duality in the segment presents a fascinating landscape in relation to market performance.  Moreover, the rise of personalized medicine and biologics is further propelling the Clinical Trials sector. Conversely, Laboratory Services benefit from technological advancements such as automation and digital integration, which are streamlining operations and enhancing service delivery, marking them as a fastest-growing segment within the industry.

Clinical Trials (Dominant) vs. Consulting Services (Emerging)

Clinical Trials remain the dominant force in the Europe Contract Research Organization Market, primarily due to their critical role in [drug development](https://www.marketresearchfuture.com/reports/drug-development-market-66529) and regulatory approval processes. This segment encapsulates various phases of clinical research, ensuring efficacy and safety for new therapeutics. On the other hand, Consulting Services are emerging as a significant player, especially as regulatory frameworks become more complex. The growing need for expert guidance on compliance and strategic planning has positioned these services as essential. Both segments showcase unique strengths, with Clinical Trials emphasizing thorough research methodologies, while Consulting Services excel in providing tailored insights and strategic advice, adapting to the evolving landscape of drug development and market entry.

### By Therapeutic Area: Oncology (Largest) vs. Cardiology (Fastest-Growing)

The Europe Contract Research Organization (CRO) market displays a diverse distribution across therapeutic areas, with Oncology accounting for the largest share due to its high demand for clinical trials and innovative treatment solutions. Cardiology, while smaller in share, is rapidly expanding as cardiovascular diseases rise, driving an increased need for research and development in this area. Neurology and Infectious Diseases also contribute to the landscape, yet their market presence is less dominant compared to the top contenders.

Oncology (Dominant) vs. Cardiology (Emerging)

Oncology remains the dominant therapeutic area in the Europe CRO market, propelled by ongoing research for cancer treatments and therapies. The complexity of oncology trials, including personalized medicine approaches, continues to attract significant investment and collaborations. On the other hand, Cardiology is identified as an emerging segment, gaining momentum due to the escalating incidence of heart-related conditions. The growing focus on chronic disease management and preventive strategies fosters innovation and research in this field, making it an appealing area for CROs seeking to expand their portfolio.

### By End User: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing)

In the Europe Contract Research Organization Market, the End User segment is primarily dominated by Pharmaceutical Companies, which holds the largest market share. This segment has benefitted from established research and development processes and strong financial backing. Biotechnology Companies, while holding a smaller share currently, are rapidly increasing their presence in the market due to innovative technologies and approaches to drug development, contributing to reshaping the industry landscape.

Pharmaceutical Companies: Dominant vs. Biotechnology Companies: Emerging

Pharmaceutical Companies are a dominant force in the Europe Contract Research Organization Market, characterized by their significant investment in R&D, extensive product pipelines, and established relationships with CROs. These companies leverage their resources for extensive clinical trials and regulatory approval processes. On the other hand, Biotechnology Companies are emerging in this space, driven by advancements in biopharmaceuticals and personalized medicine. They often focus on niche markets and specialized treatments, utilizing innovative technologies that enhance their development capabilities. This dynamic positioning signifies a shift within the sector, as smaller biotech firms increasingly partner with CROs to accelerate their product development journeys.

### By Study Phase: Phase III (Largest) vs. Phase I (Fastest-Growing)

In the Europe Contract Research Organization market, Phase III studies dominate the study phase segment due to their critical role in extensive clinical trials that validate efficacy and safety for regulatory approval. Phase II studies follow, focusing on the drug's efficacy but with a smaller participant pool. Phase I studies, although primarily assessing safety, are gaining traction as the fastest-growing segment, highlighting evolving drug development strategies and the increasing complexity of modern Therapeutics. Phase IV studies are essential post-market but traditionally attract less focus compared to Phases I-III.

Phase III: Dominant vs. Phase I: Emerging

Phase III clinical trials are pivotal in the drug development continuum, often determining a product's market viability. Known for their larger sample sizes and comprehensive efficacy assessments, they attract significant investment from pharmaceutical companies. In contrast, Phase I studies, primarily focusing on safety and dosage, are rapidly emerging as essential components of clinical development, particularly for novel therapies. The growth in Phase I studies can be attributed to advances in technology and a shift towards more innovative treatment modalities, which require thorough initial safety assessments before advancing to larger trials. This strategic focus has positioned Phase I as a critical exploration phase that is gaining momentum in the evolving landscape of the Europe Contract Research Organization market.

### By Geographical Focus: Western Europe (Largest) vs. Eastern Europe (Fastest-Growing)

The Europe Contract Research Organization Market shows a significant distribution of market share across various geographical segments. Western Europe stands out as the largest segment due to its well-established pharmaceutical and biotech industries, coupled with a robust regulatory framework that supports drug development. In contrast, Eastern Europe, while smaller in terms of total share, is emerging as a critical player due to its growing investments and favorable conditions for clinical trials.

Western Europe: Dominant vs. Eastern Europe: Emerging

Western Europe serves as the dominant region in the Europe Contract Research Organization Market, characterized by its mature infrastructure, experienced workforce, and established client bases in large pharmaceutical companies. This region benefits from advanced technological capabilities and a regulatory environment conducive to conducting clinical trials successfully. In comparison, Eastern Europe is labeled as an emerging market, driven by increasing investments in healthcare and research. Factors like cost-effectiveness, a rising number of clinical trial sites, and access to diverse patient populations make it a strategically advantageous region for CROs looking to expand their operations.

## Regional Market Share Analysis

### Germany : Strong Growth and Innovation Hub

Key markets include major cities like Berlin, Munich, and Frankfurt, which host numerous pharmaceutical companies and research institutions. The competitive landscape features prominent players such as IQVIA, Covance, and PAREXEL International, all of which have established significant operations in the region. Local market dynamics are characterized by a collaborative environment between academia and industry, fostering innovation in sectors like biotechnology and medical devices.

### UK : Innovation and Regulatory Support

Key markets include London, Cambridge, and Manchester, which are hubs for pharmaceutical research and development. The competitive landscape is dominated by major players like IQVIA and PAREXEL International, alongside emerging local firms. The business environment is dynamic, with a focus on collaboration between universities and industry, particularly in sectors like gene therapy and digital health solutions.

### France : Strong Regulatory Frameworks

Key markets include Paris, Lyon, and Marseille, which are central to pharmaceutical research and development. The competitive landscape features significant players like PAREXEL International and Charles River Laboratories. The local market dynamics are characterized by a collaborative approach between public and private sectors, particularly in the fields of oncology and neurology, fostering innovation and growth.

### Russia : Regulatory Changes and Opportunities

Key markets include Moscow and St. Petersburg, which are central to pharmaceutical research. The competitive landscape is evolving, with both local and international players like Medpace and PPD establishing a presence. The business environment is improving, with a focus on developing local capabilities in sectors such as oncology and infectious diseases, creating new opportunities for growth.

### Italy : Focus on Clinical Trials and Research

Key markets include Milan, Rome, and Bologna, which are hubs for pharmaceutical research. The competitive landscape features players like Charles River Laboratories and PAREXEL International. The local market dynamics are characterized by a collaborative environment between research institutions and industry, particularly in sectors like regenerative medicine and rare diseases, fostering innovation and growth.

### Spain : Regulatory Support and Growth Potential

Key markets include Madrid and Barcelona, which are central to pharmaceutical research. The competitive landscape features players like IQVIA and Covance, alongside local firms. The business environment is evolving, with a focus on collaboration between public institutions and private companies, particularly in sectors like oncology and infectious diseases, creating new opportunities for growth.

### Rest of Europe : Diverse Markets and Unique Challenges

Key markets include smaller nations like Belgium, Switzerland, and the Netherlands, which have emerging pharmaceutical sectors. The competitive landscape is fragmented, with a mix of local and international players. Local market dynamics vary significantly, with some countries focusing on specific therapeutic areas, such as rare diseases or personalized medicine, creating unique challenges and opportunities for CROs.

## Competitive Benchmarking

The Contract Research Organization Market in Europe is characterized by a dynamic competitive landscape, driven by increasing demand for clinical trials and the need for efficient drug development processes. Key players such as IQVIA (GB), Covance (GB), and PAREXEL International (GB) are strategically positioned to leverage their extensive experience and technological capabilities. These companies focus on innovation and digital transformation, which are essential for enhancing operational efficiency and meeting the evolving needs of pharmaceutical clients. Their collective strategies contribute to a moderately fragmented market structure, where competition is intensified by the presence of both large multinational corporations and specialized niche players.

In terms of business tactics, companies are increasingly localizing their operations to better serve regional markets and optimize supply chains. This approach not only reduces operational costs but also enhances responsiveness to client needs. The competitive structure of the market appears to be moderately fragmented, with a mix of established players and emerging firms. The influence of key players is significant, as they set industry standards and drive advancements in clinical research methodologies.

In December 2025, IQVIA (GB) announced a strategic partnership with a leading biotechnology firm to enhance its capabilities in real-world evidence generation. This collaboration is expected to bolster IQVIA's position in the market by providing clients with more comprehensive data analytics solutions, thereby improving decision-making processes in drug development. The strategic importance of this partnership lies in its potential to integrate advanced analytics with clinical trial data, which could lead to more efficient and effective drug development pathways.

In November 2025, Covance (GB) expanded its laboratory services by acquiring a specialized testing facility in Germany. This acquisition is likely to enhance Covance's service offerings in the European market, particularly in the areas of bioanalytical testing and pharmacokinetics. The strategic move underscores Covance's commitment to expanding its footprint in Europe and meeting the growing demand for specialized testing services, which is crucial for the success of clinical trials.

In October 2025, PAREXEL International (GB) launched a new digital platform aimed at streamlining the clinical trial process. This platform is designed to facilitate better communication between stakeholders and improve patient recruitment strategies. The introduction of this digital solution reflects PAREXEL's focus on leveraging technology to enhance operational efficiency and reduce time-to-market for new therapies. Such innovations are essential in a competitive landscape where speed and efficiency are paramount.

As of January 2026, current trends in the Contract Research Organization Market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into clinical research processes. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, it is anticipated that competitive differentiation will increasingly hinge on technological advancements and supply chain reliability, rather than solely on price. This shift suggests a transformative evolution in how companies compete, with a greater focus on delivering innovative solutions that enhance the overall efficiency of drug development.

## Report Scope

| MARKET SIZE 2024 | 23.6(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 25.17(USD Billion) |
| MARKET SIZE 2035 | 44.81(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.0% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | IQVIA (GB), Covance (GB), PAREXEL International (GB), Charles River Laboratories (US), Syneos Health (US), Medpace (US), PPD (US), Clinipace (US), Wuxi AppTec (CN) |
| Segments Covered | Service Type, Therapeutic Area, End User, Study Phase, Geographical Focus |
| Key Market Opportunities | Integration of advanced data analytics in clinical trials enhances efficiency in the Europe Contract Research Organization Market. |
| Key Market Dynamics | Growing emphasis on regulatory compliance drives demand for specialized services in the Europe Contract Research Organization Market. |
| Countries Covered | Germany, UK, France, Russia, Italy, Spain, Rest of Europe |

## Frequently Asked Questions

**Q: What is the current valuation of the Europe Contract Research Organization Market?**
A: The market valuation was 23.6 USD Billion in 2024.

**Q: What is the projected market size for the Europe Contract Research Organization Market by 2035?**
A: The market is expected to reach 44.81 USD Billion by 2035.

**Q: What is the expected CAGR for the Europe Contract Research Organization Market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.0% during the forecast period 2025 - 2035.

**Q: Which service type segment is projected to have the highest valuation by 2035?**
A: Clinical Trials is projected to reach 17.0 USD Billion by 2035.

**Q: How does the Oncology segment perform in the Europe Contract Research Organization Market?**
A: The Oncology segment was valued at 8.0 USD Billion in 2024 and is expected to grow to 15.0 USD Billion by 2035.

**Q: What are the key players in the Europe Contract Research Organization Market?**
A: Key players include IQVIA, Covance, PAREXEL International, and Charles River Laboratories.

**Q: What is the projected valuation for Preclinical Services by 2035?**
A: Preclinical Services is expected to reach 10.0 USD Billion by 2035.

**Q: Which geographical region is anticipated to dominate the market by 2035?**
A: Western Europe is projected to dominate with a valuation of 19.0 USD Billion by 2035.

**Q: What is the expected growth for the Phase III study segment by 2035?**
A: Phase III studies are expected to grow to 18.0 USD Billion by 2035.

**Q: How do Academic Institutions contribute to the Europe Contract Research Organization Market?**
A: Academic Institutions are projected to reach a valuation of 7.81 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/europe-cro-market-12633*